3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, hydrochloride (1:?)
-
3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, hydrochloride (1:?)
structure -
-
CAS No:
86483-48-9
-
Formula:
C17H18FN3O3.xClH
-
Chemical Name:
3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, hydrochloride (1:?)
-
Synonyms:
3-Quinolinecarboxylic acid,1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-,hydrochloride (1:?);3-Quinolinecarboxylic acid,1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-,hydrochloride
- Categories:
-
CAS No:
Description
ChEBI: The anhydrous form of the monohydrochloride salt of ciprofloxacin.
Ciprofloxacin hydrochloride (anhydrous) is the anhydrous form of the monohydrochloride salt of ciprofloxacin. It has a role as an EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor, an antibacterial drug, a topoisomerase IV inhibitor and an antiinfective agent. It contains a ciprofloxacin.|Ciprofloxacin is a second generation fluoroquinolone antibiotic that is widely used in the therapy of mild-to-moderate urinary and respiratory tract infections caused by susceptible organisms. Ciprofloxacin has been linked to rare but convincing instances of liver injury that can be severe and even fatal.|A broad-spectrum antimicrobial carboxyfluoroquinoline.
3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, hydrochloride (1:?) Basic Attributes
367.8
367.11
1806241-263-5
0MP32MFP6C
620634
DTXSID1047788
29419000
Characteristics
72.9
0.28 (non-ionized)
>300 °C
In water, 30,000 mg/L at 20 deg C
Store in tight, light-resistant container as defined in the USP-NF. This material should be handled and stored per label instructions to ensure product integrity.
2.85X10-13 mm Hg at 25 deg C (est)
Safety Information
36/37/38
26-36
Xi
The physical and chemical compatibilities of ciprofloxacin lactate infusion with other commonly used iv admin drugs /was investigated/ Ciprofloxacin lactate injection in a commercially available concn of 2 mg/ml was mixed with 15 iv drugs during a simulated Y-site injection. Of the 15 drugs /examined/ , only heparin, furosemide and teicoplanin were found to be incompatible with ciprofloxacin. /Ciprofloxacin lactate/
P261, P264, P271, P272, P273, P280, P285, P302+P352, P304+P340, P304+P341, P305+P351+P338, P312, P321, P332+P313, P333+P313, P337+P313, P342+P311, P362, P363, P391, P403+P233, P405, P501
H315
|Danger|H315 (33.33%): Causes skin irritation [Warning Skin corrosion/irritation]|P261, P264, P271, P272, P273, P280, P285, P302+P352, P304+P340, P304+P341, P305+P351+P338, P312, P321, P332+P313, P333+P313, P337+P313, P342+P311, P362, P363, P391, P403+P233, P405, and P501|Aggregated GHS information provided by 3 companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Toxicity
Ciprofloxacin like other fluoroquinolones is associated with a low rate (1% to 3%) of serum enzyme elevations during therapy. These abnormalities are generally mild, asymptomatic and transient, resolving even with continuation of therapy. More importantly, ciprofloxacin has been linked to rare, but occasionally severe and even fatal cases of acute liver injury. The time to onset is typically short (2 days to 2 weeks) and the presentation is often abrupt with nausea, fatigue and abdominal pain, followed by dark urine and jaundice. The pattern of serum enzyme elevations can be either hepatocellular or cholestatic; cases with the shorter times to onset usually being more hepatocellular with markedly elevated ALT levels, and occasionally with rapid worsening of prothrombin time and early signs of hepatic failure. The onset of illness also may occur a few days after the medication is stopped. Cases with a cholestatic pattern of enzymes may run a prolonged course, but are usually self-limiting. Nevertheless, chronic cholestasis and vanishing bile duct syndrome have been reported with ciprofloxacin and other fluoroquinolones. Finally, the enzyme pattern can be initially hepatocellular and then evolve during the course of illness from a hepatocellular into a mixed or cholestatic pattern. Many (but not all) cases have had allergic manifestations with fever, rash and eosinophilia. Autoantibodies are usually not present.
Drug Information
Treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa|Other infective otitis externa, Otitis media, unspecified
Ciprofloxacin is a second generation fluoroquinolone antibiotic that is widely used in the therapy of mild-to-moderate urinary and respiratory tract infections caused by susceptible organisms. Ciprofloxacin has been linked to rare but convincing instances of liver injury that can be severe and even fatal.
Antiinfective Agents
Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP1A2. (See all compounds classified as Cytochrome P-450 CYP1A2 Inhibitors.)|Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)|Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)
Anhydrous, Ciprofloxacin Hydrochloride
3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, hydrochloride (1:?) Use and Manufacturing
Broad-spectrum antibacterial drugs, suitable for heavy mixed infections, mainly used for chronic respiratory tract, E. coli drugs, infectious rhinitis, avian cholera, avian typhoid, etc.
Human Drugs -> EU pediatric investigation plans|Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients
Computed Properties
Molecular Weight:367.8
Hydrogen Bond Donor Count:3
Hydrogen Bond Acceptor Count:7
Rotatable Bond Count:3
Exact Mass:367.1098973
Monoisotopic Mass:367.1098973
Topological Polar Surface Area:72.9
Heavy Atom Count:25
Complexity:571
Covalently-Bonded Unit Count:2
Compound Is Canonicalized:Yes
Price Analysis
Recommended Suppliers of 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, hydrochloride (1:?)
-
![China]()
CN
5 YRS
Business licensed Certified factoryManufactory Supplier of D-Biotin,Tobramycin base,L(-)-Carnitine base,Polymyxin B sulfate USP,Kanamycin sulfate monohydrate,Finasteride 99% USP -
![China]()
CN
5 YRS
Business licensedTrader Supplier of API,nutrition supplements,plant extract,peptide,HCGInquiryCAS No.: 86483-48-9Grade: Top ProductContent: 98% -
![China]()
CN
5 YRS
Business licensed Certified factoryManufactory Supplier of Herb Extracts,Cosmetic raw materails,APIInquiryCAS No.: 86483-48-9Grade: Pharmaceutical GradeContent: 0.00% -
![China]()
CN
5 YRS
Business licensedTrader Supplier of Sodium benzoate,Potassium sorbate,Xanthan gum,phosphoric acid,citric acidInquiryCAS No.: 86483-48-9Grade: Pharmaceutical GradeContent: 99% -
![China]()
CN
5 YRS
Business licensed Certified factoryManufactory Supplier of Calcium polystyrene sulfonate,Megestrol Acetate,Eperisone Hydrochloride
Latest News on 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, hydrochloride (1:?)
Learn More Other Chemicals
-
Cyclopropanecarboxylic acid, 1-amino-2-ethenyl-, ethyl ester, hydrochloride (9CI)
681807-60-3
-
Carbonic acid, 4-[[(4-amino-2-methyl-5-pyrimidinyl)methyl]formylamino]-3-[(ethoxycarbonyl)thio]-3-penten-1-yl ethyl ester, hydrochloride (1:1)
616-96-6
-
Carbamic acid, N-[2-(heptyloxy)phenyl]-, 2-(1-piperidinyl)ethyl ester, hydrochloride (1:1)
55792-21-7
-
Benzeneacetic acid, α-imino-3,4-dimethoxy-, methyl ester, hydrochloride (1:1) Formula
67828-59-5
-
Butanedioic acid, 1-[2-(2-chloro-5-methylphenoxy)-1-[[(1,1-dimethylethyl)amino]methyl]ethyl] 4-[2-[(1-oxohexadecyl)oxy]-1-[[(1-oxohexadecyl)oxy]methyl]ethyl] ester, hydrochloride (1:1) Formula
99026-79-6
-
Carbamimidothioic acid, C,C′-2,3-quinoxalinediyl ester, hydrochloride (1:2) Formula
63549-18-8
-
Benzeneacetic acid, 2,4-dihydroxy-α-imino-, ethyl ester, hydrochloride (1:1) Structure
35092-73-0
-
21H,23H-Porphine-2,18-dipropanoic acid, 3,7,12,17-tetramethyl-8,13-disulfo-, hydrochloride (1:2) Structure
623946-74-7
-
What is 21H,23H-Porphine-2,7,12,18-tetrapropanoic acid, 3,8,13,17-tetramethyl-, hydrochloride (1:2)
68938-73-8
-
What is Propanoic acid, 2-(4-chlorophenoxy)-2-methyl-, [6-(hydroxymethyl)-2-pyridinyl]methyl ester, hydrochloride (1:1)
21550-30-1
3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, hydrochloride (1:?)
SDSRequest for Quotation